MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 110 participants.

Also called NCT07685886

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 110 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07685886
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07685886. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2031-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes
Acronym
MIRACLE-T2D
Condition
Diabetes
Condition
Kidney Disease
Condition
Vascular Disease
Condition
Retinopathy
Intervention (Drug)
Montelukast
Intervention (Drug)
Placebo
Lead sponsor
University of Colorado, Denver (class: other)

Record details

Record id
cardio:ct-nct07685886
Content hash
6c8f49169d349d520e4aa6cedca5741b30dbf286d5e3316b44d42d9d9d471986